Latest News about RETA
Recent news which mentions RETA
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
From Benzinga
An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
October 05, 2023
From Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
September 09, 2023
From Motley Fool
Tags
Stocks to Buy
Market News
NASDAQ:MNKD,NYSE:JNJ,NASDAQ:BIIB,NASDAQ:RETA,NYSE:LLY,NASDAQ:IMGN,NYSE:MRK,NYSE:NVO
From InvestorPlace
The 7 Most Promising Momentum Stocks to Own Now
August 31, 2023
From InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
August 30, 2023
From InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
August 14, 2023
From Benzinga
With an Acquisition on the Way, Is Biogen Stock a Buy?
August 09, 2023
From Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
August 08, 2023
From Benzinga
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023
August 01, 2023
From Benzinga
From Motley Fool
From Benzinga
Could This Stock Be the Next Biotech Buyout?
July 31, 2023
From Motley Fool
From Benzinga
From Benzinga
Why Avantor Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 28, 2023
From Benzinga
From Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
July 28, 2023
From Benzinga
From Benzinga
From MarketWatch
Skechers, Chart Industries, Roku, Beazer Homes And Other Big Stocks Moving Higher On Friday
July 28, 2023
From Benzinga
Why Is QuantumScape (QS) Stock Up 10% Today?
July 28, 2023
From InvestorPlace
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
July 28, 2023
From InvestorPlace
From Benzinga
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
July 28, 2023
From Benzinga
From Benzinga
Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
July 28, 2023
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.